11 - 14 November 2024, Düsseldorf, Germany.
Siemens Healthineers is joining forces with more than 20 industry and public partners, including seven leading stroke hospitals, to improve stroke management for patients all over Europe. With a total volume of €26.9 million, the five-year UMBRELLA(1) project is partly funded by the Innovative Health Initiative (IHI), a public-private partnership for health research and innovation between the European Union and Europe's life science industries, and partly by the industry partners participating in the consortium.
Covered recently in the prestigious journal Nature Medicine, BiomedGPT is a new a new type of artificial intelligence (AI) designed to support a wide range of medical and scientific tasks.
11 - 14 November 2024, Düsseldorf, Germany.
Emergency departments in three hospitals across Hampshire Hospitals NHS Foundation Trust have deployed Alcidion's Miya Emergency, digitising paper processes, saving clinical teams time, automating tasks, and providing trust-wide visibility of patient status and A&E activity.
Clinical professionals and end users were deeply involved in this complex undertaking, from the moment a decision was made to deliver a new emergency department electronic patient record.
NHS organisations will be able to save valuable time and resource in the procurement of technologies that can make a significant difference to patient experience, in the latest iteration of the government’s G-Cloud procurement framework.
Airwave Healthcare, which works with hospitals to deliver affordable and innovative technologies to help to entertain, educate and inform patients, is for the first time making its services available through the G-Cloud framework.
The study was conducted with 50 U.S.-licensed physicians in family medicine, internal medicine and emergency medicine.
11 - 14 November 2024, Düsseldorf, Germany.The computational tool is called PIONEER (Protein-protein InteractiOn iNtErfacE pRediction). Researchers demonstrated PIONEER's utility by identifying potential drug targets for dozens of cancers and other complex diseases in a recently published Nature Biotechnology article.